Login to Your Account



Value, not price: Gilead defends Sovaldi premium pricing

By Jennifer Boggs
Managing Editor

Tuesday, January 14, 2014
SAN FRANCISCO – Gilead Sciences Inc.’s breakthrough hepatitis C virus (HCV) drug Sovaldi (sofosbuvir), which gained approval in the U.S. in December and got off to a strong start despite typical slowdown of the holidays, is expected to be approved in Europe later this month, likely with favorable pricing.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription